BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35196945)

  • 1. Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
    Samoon Z; Naher SK; Sjoquist KM; Zalcberg J
    Expert Opin Pharmacother; 2022 Apr; 23(6):663-672. PubMed ID: 35196945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
    Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
    Alberts S; Poston G
    Colorectal Dis; 2003 Nov; 5 Suppl 3():20-8. PubMed ID: 23573557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specific treatment situations in metastatic colorectal cancer].
    Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
    Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.
    Ochiai T; Masuda T; Yagi M; Kasai R; Furuyama T; Tsukamoto K; Ito H; Igari K; Aihara A; Kumagai Y; Iida M; Odajima H; Tanaka S; Arii S; Yamazaki S
    Int Surg; 2012; 97(1):6-13. PubMed ID: 23101994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?
    Lubezky N; Geva R; Shmueli E; Nakache R; Klausner JM; Figer A; Ben-Haim M
    World J Surg; 2009 May; 33(5):1028-34. PubMed ID: 19234865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
    Hebbar M; Pruvot FR; Romano O; Triboulet JP; de Gramont A
    Cancer Treat Rev; 2009 Dec; 35(8):668-75. PubMed ID: 19733977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
    Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R
    BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
    Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Following Treatment with FOLFOX for Patients with Resectable or Potentially Resectable Metastatic Colorectal Cancer: A Population-based Cohort Study.
    Habbous S; Tai X; Gill T; Arias J; Beca J; Raphael MJ; Kennedy E; Biagi JJ; Chan KKW
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):188-198. PubMed ID: 36610878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
    Takatsuki M; Tokunaga S; Uchida S; Sakoda M; Shirabe K; Beppu T; Emi Y; Oki E; Ueno S; Eguchi S; Akagi Y; Ogata Y; Baba H; Natsugoe S; Maehara Y;
    Eur J Surg Oncol; 2016 Feb; 42(2):184-9. PubMed ID: 26683263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
    Min BS; Kim NK; Ahn JB; Roh JK; Kim KS; Choi JS; Cha SH; Kim H
    Onkologie; 2007 Dec; 30(12):637-43. PubMed ID: 18063876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
    Nasti G; Piccirillo MC; Izzo F; Ottaiano A; Albino V; Delrio P; Romano C; Giordano P; Lastoria S; Caracò C; de Lutio di Castelguidone E; Palaia R; Daniele G; Aloj L; Romano G; Iaffaioli RV
    Br J Cancer; 2013 Apr; 108(8):1566-70. PubMed ID: 23558891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
    Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Alberts SR; Horvath WL; Sternfeld WC; Goldberg RM; Mahoney MR; Dakhil SR; Levitt R; Rowland K; Nair S; Sargent DJ; Donohue JH
    J Clin Oncol; 2005 Dec; 23(36):9243-9. PubMed ID: 16230673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases.
    Benoist S; Nordlinger B
    Ann Surg Oncol; 2009 Sep; 16(9):2385-90. PubMed ID: 19554377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
    BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.